Analysts expect Keryx Biopharmaceuticals (NASDAQ:KERX) to post $21.12 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Keryx Biopharmaceuticals’ earnings, with estimates ranging from $19.09 million to $22.95 million. Keryx Biopharmaceuticals reported sales of $11.82 million in the same quarter last year, which would suggest a positive year over year growth rate of 78.7%. The company is scheduled to announce its next earnings report on Thursday, May 3rd.
On average, analysts expect that Keryx Biopharmaceuticals will report full-year sales of $21.12 million for the current year, with estimates ranging from $99.97 million to $114.31 million. For the next financial year, analysts anticipate that the business will post sales of $162.01 million per share, with estimates ranging from $159.00 million to $163.88 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Keryx Biopharmaceuticals.
Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.08). The company had revenue of $18.70 million for the quarter, compared to analysts’ expectations of $17.53 million. Keryx Biopharmaceuticals had a negative net margin of 269.52% and a negative return on equity of 10,954.62%. The business’s revenue was up 96.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.32) EPS.
A number of analysts have recently issued reports on KERX shares. BidaskClub downgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, March 6th. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 1st. ValuEngine downgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, February 22nd. Finally, Morgan Stanley dropped their price objective on shares of Keryx Biopharmaceuticals from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, February 8th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $7.19.
In related news, insider Greg Madison sold 15,318 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $4.81, for a total value of $73,679.58. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Scott A. Holmes sold 5,651 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $4.81, for a total transaction of $27,181.31. The disclosure for this sale can be found here. In the last three months, insiders sold 43,182 shares of company stock worth $208,175. 2.58% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Abrams Capital Management L.P. boosted its holdings in shares of Keryx Biopharmaceuticals by 69.9% in the fourth quarter. Abrams Capital Management L.P. now owns 9,719,176 shares of the biopharmaceutical company’s stock worth $45,194,000 after buying an additional 4,000,000 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Keryx Biopharmaceuticals by 1.9% in the fourth quarter. BlackRock Inc. now owns 6,097,948 shares of the biopharmaceutical company’s stock worth $28,356,000 after buying an additional 112,381 shares during the last quarter. Clearbridge LLC boosted its holdings in shares of Keryx Biopharmaceuticals by 67.7% in the fourth quarter. Clearbridge LLC now owns 2,692,744 shares of the biopharmaceutical company’s stock worth $12,521,000 after buying an additional 1,087,120 shares during the last quarter. Rice Hall James & Associates LLC boosted its holdings in shares of Keryx Biopharmaceuticals by 19.4% in the fourth quarter. Rice Hall James & Associates LLC now owns 1,911,657 shares of the biopharmaceutical company’s stock worth $8,889,000 after buying an additional 310,485 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Keryx Biopharmaceuticals by 1.1% in the third quarter. Bank of New York Mellon Corp now owns 973,229 shares of the biopharmaceutical company’s stock worth $6,910,000 after buying an additional 10,175 shares during the last quarter. 65.36% of the stock is currently owned by institutional investors.
Shares of Keryx Biopharmaceuticals stock opened at $4.53 on Monday. The company has a current ratio of 3.12, a quick ratio of 2.49 and a debt-to-equity ratio of -8.87. Keryx Biopharmaceuticals has a 1-year low of $4.01 and a 1-year high of $8.38.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/19/21-12-million-in-sales-expected-for-keryx-biopharmaceuticals-kerx-this-quarter.html.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Get a free copy of the Zacks research report on Keryx Biopharmaceuticals (KERX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.